Copeptin in Autosomal Dominant Polycystic Kidney Disease (AdPKD)

AdPKD (Autosomal Dominant Polycystic Kidney Disease) is the fourth leading cause of end-stage renal disease (ESRD) worldwide but there is high variability in disease progression. Copeptin, an accurate surrogate marker of Vasopressin (AVP), correlates with disease severity in AdPKD, and predicts the decline in renal function and increase in Total Kidney Volume; therefore it may be used to select patients groups who will benefit the most for specific medical or life style treatments options and to monitor the effectiveness of such treatment.


Free webinar about Autosomal Dominant Polycystic Kidney Disease (AdPKD)

icon webinarThis webinar will review the available clinical evidences and the ongoing studies that will support establishing Copeptin as a marker in AdPKD

Attend free webinar on AdPKD >


Agenda of the webinar

Day & location: 26th of May 2018, 16:15 -16:45 PM (CEST), Room C1-M0, ERA-EDTA 2018 Congress, Copenhagen.

Title: Improving prognosis and treatment response in AdPKD: role of Copeptin

Speaker: Dr. Roman-Ulrich Müller, University Hospital Cologne (Germany)


  1. AdPKD: Disease Overview
  2. Open topics: is there a need to accurately predict renal prognosis and treatment response?
  3. Role of biomarkers: Copeptin overview and its potential role in AdPKD
  4. Ongoing studies that could support the implementation of Copeptin in AdPKD


thermo scientific applied biosystems invitrogen fisher scientific unity lab service